Bioventix Share Discussion Threads

[gsbmba99] 20/1/2020 15:15

A behind the scenes look at the switch to hs-troponin at two hospitals. Not much new. Confirmation of significant savings on discharge following zero hour and zero/two hour troponin results. Dr. Apple is in favour of manufacturers discontinuing the old assay.

[stepone68] 20/1/2020 14:33

Think you'll find it's been better as LTBH. Any trader would have taken a quick profit years ago, and still be waiting for an entry point to get back in...!

[11_percent] 20/1/2020 14:12

Sounds like a good strategy......this has been a good a good trading share.

[diviincomesearch] 20/1/2020 13:30

Sold my remaining holding here this morning.

This bounce has been great- however we need positive results on troponin and vitamin d revenue to plough on.

If things dip back down to 3500 territory then I’ll look to get back in again.

[trident5] 17/1/2020 09:42

Or - is something else going on here?

[11_percent] 17/1/2020 09:26

That was some share tip.....

[stepone68] 16/1/2020 15:59

This pretty much doubles every two years. Long may it continue :-)

[chester] 16/1/2020 14:24

On the verge of a major breakout to New Highs.

[igbertsponk] 16/1/2020 13:46

Nice to be back over £40. Hope it holds.

[igbertsponk] 15/1/2020 09:26

Yes it will crash. As all the shareholders are disloyal short-term punters....
Amusing.

[stepone68] 15/1/2020 08:46

When did they report a year of 1% sales growth?

[mastermasterbaker] 15/1/2020 06:23

If they report another year of 1% sales growth this will crash

[a1samu] 13/1/2020 16:39

On a shareprice of £39.00 the yield is 3.08% if the special div is included which gives a div of £1.20 last year!

To be more annuity like should the yield reduce to perhaps 1.5%. Even FGT shows a yield of below 2%.

To yield 2% the share would have to be on £60.00.

[stepone68] 13/1/2020 14:02

That's just a Tweet linking to the same article that has already been discussed, and quoted in its entirety just above...! And to access it I was forced to follow that twitter account which I assume belongs to you? Well, I've unfollowed and blocked it after that experience.

[scillyfool] 10/1/2020 16:18

One of my best AIM buys. Bought over 4 years ago. My initial reasons for buying were that BVXP was a very small company (only 13 employees), no debts, a unique product which has a huge potential, a dividend rising at 30% p.a. (Subsequently dropped to only 20% increases p.a!), throwing off a lot of surplus cash. Didn't appear in many financial articles. Very large moat.

Now has a potential tie up with Siemens and still below its peak price of £41. Only one broker following the share (I think this may change shortly). Up over 10% today alone!

[diviincomesearch] 10/1/2020 08:48

Oh dear- isn’t that the kiss of death when Questor tips things with their track record!

I don’t have premium so if someone could post the full article that would be good.

[mngf] 10/1/2020 08:15

Tipped by Questor

[diviincomesearch] 08/1/2020 18:29

Yes, slowly grinding upwards. I don’t see the share price having much upwards momentum unless there’s some serious news on troponin at the next results.

The share price is still fairly rich based on the latest results.

[igbertsponk] 08/1/2020 17:01

HNY holders - gradually creeping back up where she belongs.

[sharesoc] 19/12/2019 18:42

There is a detailed report on Bioventix's recent AGM which can be found in our members area here:

To access the report, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here:

Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the report (and reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here:

[chippyfriday] 19/12/2019 16:05

Hopefully significant



Objectives To directly compare the diagnostic accuracy of four decision aids (Troponin-only Manchester Acute Coronary Syndromes (T-MACS), History, ECG, Age, Risk factors and Troponin (HEART), Thrombolysis in Myocardial Infarction (TIMI) and Emergency Department Assessment of Chest Pain (EDACS)) used to expedite the early diagnosis of acute coronary syndromes (ACS) in the ED.

Conclusions In this study, T-MACS could rule out AMI in 46.5% patients with 99.2% sensitivity. EDACS could rule out AMI in 48.3% patients with lower sensitivity, although the difference was not statistically significant. The HEART and TIMI scores had lower diagnostic accuracy.

[gsbmba99] 19/12/2019 09:11

The CEO of CardiNor is presenting at Swiss-Nordic Bio in February. CardiNor is developing a secretoneurin assay using a Bioventix antibody. Secretoneurin is an experimental cardiac biomarker for which clinical utility has not yet been established. This year's version of his profile indicates that "The first product is now ready for launch in the research market" and that they are seeking to raise Eur 2m to pursue CE marking. Encouraging that RuO (research use only) launch of secretoneurin is imminent and that things are, more generally, progressing. RuO sales unlikely to be meaningful as secretoneurin not currently widely researched.